<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118559</article-id><article-id pub-id-type="publisher-id">ACM-44888</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_56714423.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  心房颤动患者射频消融术后复发的危险因素研究
  Study on Risk Factors for Recurrence after Radiofrequency Ablation in Patients with Atrial Fibrillation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>凯杨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>茂敬</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蔡</surname><given-names>尚郎</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院心血管内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3806</fpage><lpage>3812</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨心房颤动患者经过射频消融治疗后复发的危险因素。方法：纳入于2019年1月至2020年1月就诊于青岛大学附属医院并行射频消融治疗的房颤患者96例，术后随访12个月，根据是否出现空窗期(术后3个月)后房颤复发分为复发组(n = 25)和非复发组(n = 71)，收集2组患者的临床资料，探索房颤复发的影响因素。结果：2组患者的年龄、性别、BMI、合并高血压病、冠心病、糖尿病、CHA2DS2-VASc评分、HAS-BLED评分、BNP水平无统计学差异，2组患者的房颤类型、房颤病程、左房前后径、左房容积指数、左心室射血分数、术中标测术中是否存在左房低电压区、血清尿酸、血清同型半胱氨酸水平存在统计学差异。多因素Logistic回归分析发现左房前后径、左房容积指数、存在左房低电压区、血清尿酸水平与射频消融术后房颤复发独立相关，其ROC曲线下面积及95%置信区间分别为0.942 (0.899~0.984)，0.801 (0.712~0.889)，0.957 (0.920~0.993)，0.644 (0.517~0.771)。结论：左房前后径大、左房容积指数高、存在左房低电压区、血清尿酸高与射频消融术后房颤复发独立相关。
   Objective: To explore the risk factors of recurrence after radiofrequency ablation in patients with atrial fibrillation. Methods: A total of 96 patients with atrial fibrillation, who were treated with radiofrequency ablation from January 2019 to January 2020, were enrolled into this study. All patients were divided into 2 groups according to the 12-month follow-up results after the surgery, including recurrence group (n = 25) and non-recurrence group (n = 71). Clinical data of 2 patients were collected to explore the influencing factors of AF recurrence. Results: There were no statistical differences in age, sex, BMI, hypertension, coronary heart disease, diabetes, CHA2DS2-VASc score, HAS-BLED score and BNP level, while there were significant statistical differences in types of atrial fibrillation, time of atrial fibrillation, left atrial diameter, left atrial volume index, left ventricular ejection fraction, LV low voltage area, serum uric acid and serum homocysteine levels. Multi-factor logistic regression analysis found that left atrial diameter, left atrial volume index, presence of left atrial low voltage area, serum uric acid levels were independently associated with AF recurrence after radiofrequency ablation, the area under the curve and 95% confidence interval of these factors were 0.942 (0.899~0.984), 0.801 (0.712~0.889), 0.957 (0.920~0.993), 0.644 (0.517~0.771). Conclusion: The large left atrial diameter, high left atrial volume index, presence low left atrial voltage area, high serum uric acid were independently associated with the recurrence of AF after radiofrequency ablation.
 
</p></abstract><kwd-group><kwd>心房颤动，射频消融术，复发, Atrial Fibrillation</kwd><kwd> Radiofrequency Ablation</kwd><kwd> Recurrence</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨心房颤动患者经过射频消融治疗后复发的危险因素。方法：纳入于2019年1月至2020年1月就诊于青岛大学附属医院并行射频消融治疗的房颤患者96例，术后随访12个月，根据是否出现空窗期(术后3个月)后房颤复发分为复发组(n = 25)和非复发组(n = 71)，收集2组患者的临床资料，探索房颤复发的影响因素。结果：2组患者的年龄、性别、BMI、合并高血压病、冠心病、糖尿病、CHA<sub>2</sub>DS<sub>2</sub>-VASc评分、HAS-BLED评分、BNP水平无统计学差异，2组患者的房颤类型、房颤病程、左房前后径、左房容积指数、左心室射血分数、术中标测术中是否存在左房低电压区、血清尿酸、血清同型半胱氨酸水平存在统计学差异。多因素Logistic回归分析发现左房前后径、左房容积指数、存在左房低电压区、血清尿酸水平与射频消融术后房颤复发独立相关，其ROC曲线下面积及95%置信区间分别为0.942 (0.899~0.984)，0.801 (0.712~0.889)，0.957 (0.920~0.993)，0.644 (0.517~0.771)。结论：左房前后径大、左房容积指数高、存在左房低电压区、血清尿酸高与射频消融术后房颤复发独立相关。</p></sec><sec id="s2"><title>关键词</title><p>心房颤动，射频消融术，复发</p></sec><sec id="s3"><title>Study on Risk Factors for Recurrence after Radiofrequency Ablation in Patients with Atrial Fibrillation<sup> </sup></title><p>Kaiyang Li<sup>*</sup>, Maojing Wang, Shanglang Cai<sup>#</sup></p><p>Department of Cardiovascular Medicine, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/76-1572473x5_hanspub.png?20210831082134410" /></p><p>Received: Jul. 26<sup>th</sup>, 2021; accepted: Aug. 23<sup>rd</sup>, 2021; published: Aug. 30<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/76-1572473x6_hanspub.png?20210831082134410" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the risk factors of recurrence after radiofrequency ablation in patients with atrial fibrillation. Methods: A total of 96 patients with atrial fibrillation, who were treated with radiofrequency ablation from January 2019 to January 2020, were enrolled into this study. All patients were divided into 2 groups according to the 12-month follow-up results after the surgery, including recurrence group (n = 25) and non-recurrence group (n = 71). Clinical data of 2 patients were collected to explore the influencing factors of AF recurrence. Results: There were no statistical differences in age, sex, BMI, hypertension, coronary heart disease, diabetes, CHA<sub>2</sub>DS<sub>2</sub>-VASc score, HAS-BLED score and BNP level, while there were significant statistical differences in types of atrial fibrillation, time of atrial fibrillation, left atrial diameter, left atrial volume index, left ventricular ejection fraction, LV low voltage area, serum uric acid and serum homocysteine levels. Multi-factor logistic regression analysis found that left atrial diameter, left atrial volume index, presence of left atrial low voltage area, serum uric acid levels were independently associated with AF recurrence after radiofrequency ablation, the area under the curve and 95% confidence interval of these factors were 0.942 (0.899~0.984), 0.801 (0.712~0.889), 0.957 (0.920~0.993), 0.644 (0.517~0.771). Conclusion: The large left atrial diameter, high left atrial volume index, presence low left atrial voltage area, high serum uric acid were independently associated with the recurrence of AF after radiofrequency ablation.</p><p>Keywords:Atrial Fibrillation, Radiofrequency Ablation, Recurrence</p><disp-formula id="hanspub.44888-formula33"><graphic xlink:href="//html.hanspub.org/file/76-1572473x7_hanspub.png?20210831082134410"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/76-1572473x8_hanspub.png?20210831082134410" /> <img src="//html.hanspub.org/file/76-1572473x9_hanspub.png?20210831082134410" /></p></sec><sec id="s5"><title>1. 引言</title><p>心房颤动(atrial fibrillation, AF)是临床上最常见的心律失常之一，在我国的发病率约为0.64% [<xref ref-type="bibr" rid="hanspub.44888-ref1">1</xref>]，而且随着年龄的增长，房颤的患病率逐渐升高，因此，可以预见随着人均寿命延长，人群中房颤的发病率会进一步升高。目前导管消融已经作为症状性房颤治疗的首选治疗方案 [<xref ref-type="bibr" rid="hanspub.44888-ref2">2</xref>]，可有效地控制症状，维持窦性心律。但射频消融术后较高的复发率成为患者及临床医生关注的问题 [<xref ref-type="bibr" rid="hanspub.44888-ref3">3</xref>]，因此，明确房颤复发的危险因素，针对相关因素采取综合干预措施，可能在一定程度上减少房颤射频消融手术的复发率。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>纳入于2019年1月至2020年1月就诊于青岛大学附属医院心血管内科并行射频消融术的心房颤动患者96例，所有患者术后均随访12个月，根据3个月空窗期后是否出现房颤复发分为复发组25例和非复发组71例。收集2组患者的临床资料，包括年龄、性别、BMI、房颤类型、房颤病史、CHA<sub>2</sub>DS<sub>2</sub>-VASc评分、HAS-BLED评分、左房前后径、左心室射血分数、左心房低电压区、血清尿酸、血清同型半胱氨酸、BNP及是否存在高血压病、冠心病、糖尿病合并症等。房颤复发定义为：在接受射频消融手术3个月(空窗期)后出现持续时间 ≥ 30 s的心房颤动、心房扑动或房性心动过速。本研究通过青岛大学附属医院伦理委员会审批通过，所有研究对象均签署知情同意书。</p></sec><sec id="s6_2"><title>2.2. 纳入与排除标准</title><p>纳入标准：1) 经标准12导联心电图、24小时动态心电图等检查确诊为心房颤动；2) 无射频消融手术禁忌症。排除标准：1) 存在需要手术治疗的心脏瓣膜病；2) 有出血性疾病、严重肝肾功能不全、恶性肿瘤、甲状腺功能亢进未予纠正；3) 此前曾接受过心脏射频消融手术。</p></sec><sec id="s6_3"><title>2.3. 研究方法</title><p>术前常规完善经胸超声心动图了解心功能、心脏结构是否存在异常，并测量左房大小、左心室射血分数等数据，通过左房大小、身高、体重计算左房容积指数的方法为：根据椭圆公式计算左心房容积(LAV) = (4π/3) &#215; (左右径/2) &#215; (上下径/2)，体表面积(BSA) = 0.0124 &#215; 体重(kg) + 0.0061 &#215; 身高(cm) − 0.1529，LAVI = LAV/BSA [<xref ref-type="bibr" rid="hanspub.44888-ref4">4</xref>]。经食管超声心动图排除心房及心耳血栓。术前服用华法林或新型口服抗凝药的患者均在手术当天停用，服用华法林抗凝的患者规律监测INR。术前禁饮食6~8小时。术中穿刺右侧股静脉置入冠状窦电极，并通过右侧股静脉完成房间隔穿刺，在CARTO三维电生理标测系统(强生公司，美国)辅助下应用星形标测导管完成左心房三维重建，标测左心房是否存在低电压区，应用SmartTouch压力感知导管完成环肺静脉隔离，在术中即刻进行肺静脉双向隔离验证，若术中房颤未终止则加以线性消融和/或基质改良。若患者房颤仍未终止则在镇静状态下行150 J同步直流电复律。术后3个月内应用抗心律失常药物和抗凝药物，并在术后1个月、3个月、6个月、12个月行24小时动态心电图检查，若患者存在房颤相关症状则立即就近到医院行心电图检查。</p></sec><sec id="s6_4"><title>2.4. 统计学处理</title><p>采用SPSS 22.0软件对数据进行统计分析。计量资料以 x &#175; &#177; s表示，组间比较采用独立样本t检验；计数资料以频数或率(%)表示，比较采用Χ<sup>2</sup>检验；将单因素分析中P &lt; 0.10变量纳入多变量回归模型，采用Logistic回归分析评估相关因素对房颤复发的预测价值。P &lt; 0.05定义为差异具有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 基线资料</title><p>本研究共纳入96例患者，其中阵发性房颤61例(63.54%)，持续性房颤35例(36.46%)，平均房颤病程(13.31 &#177; 5.63)月。所有患者均术后随访12个月，有25例患者(26.04%)发生复发，71例患者(73.96%)未复发。所有患者的临床资料如表1。研究发现房颤类型为持续性房颤、房颤病程、左房前后径、左房容积指数、左室射血分数、左房存在低电压区、尿酸水平、血清同型半胱氨酸水平与射频消融术后房颤复发有关。</p></sec><sec id="s7_2"><title>3.2. 多因素Logistic回归分析探索房颤复发的独立影响因素</title><p>建立非条件Logistic回归分析模型，以是否出现房颤复发作为因变量，赋值1 = 复发，0 = 未复发；以上述单因素分析(表1)中P &lt; 0.10的因素或指标为自变量，包括房颤的类型、房颤病程、左房前后径、左房容积指数、左心室射血分数、是否存在左房低电压区、血清尿酸水平、血清同型半胱氨酸水平。为提高统计效率，经过对已有资料的分析，将连续型数值变量按2组合并后的中位数进行分层，转化为二分类变量。发现左房前后径、左房容积指数、是否存在左房低电压区、血清尿酸水平与房颤复发相关。结果如表2。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of clinical data between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >复发组(n = 25)</th><th align="center" valign="middle" >未复发组(n = 71)</th><th align="center" valign="middle" >t/Χ<sup>2</sup>值</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >64.88 &#177; 7.15</td><td align="center" valign="middle" >66.70 &#177; 7.96</td><td align="center" valign="middle" >1.252</td><td align="center" valign="middle" >0.266</td></tr><tr><td align="center" valign="middle" >性别(男性)</td><td align="center" valign="middle" >16 (17.58%)</td><td align="center" valign="middle" >37 (40.65%)</td><td align="center" valign="middle" >1.057</td><td align="center" valign="middle" >0.304</td></tr><tr><td align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >25.95 &#177; 3.38</td><td align="center" valign="middle" >25.55 &#177; 3.10</td><td align="center" valign="middle" >0.295</td><td align="center" valign="middle" >0.588</td></tr><tr><td align="center" valign="middle" >合并高血压病</td><td align="center" valign="middle" >19 (20.88%)</td><td align="center" valign="middle" >53 (58.24%)</td><td align="center" valign="middle" >0.018</td><td align="center" valign="middle" >0.893</td></tr><tr><td align="center" valign="middle" >合并冠心病</td><td align="center" valign="middle" >14 (15.38%)</td><td align="center" valign="middle" >51 (56.04%)</td><td align="center" valign="middle" >2.119</td><td align="center" valign="middle" >0.145</td></tr><tr><td align="center" valign="middle" >合并糖尿病</td><td align="center" valign="middle" >10 (10.99%)</td><td align="center" valign="middle" >27 (29.67%)</td><td align="center" valign="middle" >0.03</td><td align="center" valign="middle" >0.862</td></tr><tr><td align="center" valign="middle" >房颤类型</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阵发性房颤</td><td align="center" valign="middle" >10 (10.99%)</td><td align="center" valign="middle" >51 (56.04%)</td><td align="center" valign="middle" >8.087</td><td align="center" valign="middle" >0.004</td></tr><tr><td align="center" valign="middle" >持续性房颤</td><td align="center" valign="middle" >15 (16.48%)</td><td align="center" valign="middle" >20 (21.98%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >房颤病程(月)</td><td align="center" valign="middle" >15.28 &#177; 7.06</td><td align="center" valign="middle" >12.62 &#177; 4.90</td><td align="center" valign="middle" >4.274</td><td align="center" valign="middle" >0.041</td></tr><tr><td align="center" valign="middle" >CHA<sub>2</sub>DS<sub>2</sub>-VASc评分</td><td align="center" valign="middle" >4.36 &#177; 1.96</td><td align="center" valign="middle" >4.42 &#177; 1.86</td><td align="center" valign="middle" >0.020</td><td align="center" valign="middle" >0.887</td></tr><tr><td align="center" valign="middle" >HAS-BLED评分</td><td align="center" valign="middle" >2.52 &#177; 1.33</td><td align="center" valign="middle" >2.37 &#177; 1.15</td><td align="center" valign="middle" >0.305</td><td align="center" valign="middle" >0.582</td></tr><tr><td align="center" valign="middle" >左房前后径(mm)</td><td align="center" valign="middle" >46.96 &#177; 4.41</td><td align="center" valign="middle" >38.37 &#177; 4.21</td><td align="center" valign="middle" >75.264</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >左房容积指数(mL/m<sup>2</sup>)</td><td align="center" valign="middle" >50.04 &#177; 12.11</td><td align="center" valign="middle" >38.11 &#177; 9.61</td><td align="center" valign="middle" >24.751</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >左室射血分数(%)</td><td align="center" valign="middle" >57.16 &#177; 3.25</td><td align="center" valign="middle" >59.61 &#177; 3.66</td><td align="center" valign="middle" >8.733</td><td align="center" valign="middle" >0.004</td></tr><tr><td align="center" valign="middle" >左房低电压区(例)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >存在</td><td align="center" valign="middle" >9 (9.89%)</td><td align="center" valign="middle" >46 (50.55%)</td><td align="center" valign="middle" >6.263</td><td align="center" valign="middle" >0.012</td></tr><tr><td align="center" valign="middle" >不存在</td><td align="center" valign="middle" >16 (17.58%)</td><td align="center" valign="middle" >25 (27.47%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >尿酸(mmol/L)</td><td align="center" valign="middle" >493.92 &#177; 61.81</td><td align="center" valign="middle" >325.85 &#177; 74.35</td><td align="center" valign="middle" >102.574</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >同型半胱氨酸(μmmol/L)</td><td align="center" valign="middle" >21.72 &#177; 3.73</td><td align="center" valign="middle" >17.82 &#177; 3.90</td><td align="center" valign="middle" >18.917</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >BNP (pg/ml)</td><td align="center" valign="middle" >160.42 &#177; 98.89</td><td align="center" valign="middle" >168.42 &#177; 108.82</td><td align="center" valign="middle" >0.106</td><td align="center" valign="middle" >0.745</td></tr></tbody></table></table-wrap><p>表1. 2组患者的临床资料比较</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Multivariate logistic regression analysis of influencing factors of atrial fibrillation recurrence after radiofrequency ablatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >因素</th><th align="center" valign="middle" >B</th><th align="center" valign="middle" >SE</th><th align="center" valign="middle" >Wald Χ<sup>2</sup></th><th align="center" valign="middle" >OR (95%CI)</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >左房前后径</td><td align="center" valign="middle" >2.382</td><td align="center" valign="middle" >0.954</td><td align="center" valign="middle" >6.236</td><td align="center" valign="middle" >10.823 (1.669~70.171)</td><td align="center" valign="middle" >0.013</td></tr><tr><td align="center" valign="middle" >左房容积指数</td><td align="center" valign="middle" >2.059</td><td align="center" valign="middle" >0.915</td><td align="center" valign="middle" >5.062</td><td align="center" valign="middle" >7.841 (1.304~47.147)</td><td align="center" valign="middle" >0.024</td></tr><tr><td align="center" valign="middle" >是否存在左房低电压区</td><td align="center" valign="middle" >1.707</td><td align="center" valign="middle" >0.778</td><td align="center" valign="middle" >4.814</td><td align="center" valign="middle" >0.181 (0.040~0.834)</td><td align="center" valign="middle" >0.028</td></tr><tr><td align="center" valign="middle" >血清尿酸水平</td><td align="center" valign="middle" >2.852</td><td align="center" valign="middle" >0.858</td><td align="center" valign="middle" >11.057</td><td align="center" valign="middle" >17.322 (3.225~93.038)</td><td align="center" valign="middle" >0.001</td></tr></tbody></table></table-wrap><p>表2. 射频消融术后房颤复发影响因素的多因素Logistic回归分析</p></sec><sec id="s7_3"><title>3.3. 受试者工作特征曲线(ROC)评价各因素预测房颤复发的效能</title><p>对2组患者的左房前后径、左房容积指数、是否存在左房低电压区、血清尿酸水平进行ROC曲线分析，结果显示，曲线下面积(AUC)及95%置信区间(95%CI)分别为0.942 (0.899~0.984)，0.801 (0.712~0.889)，0.957 (0.920~0.993)，0.644 (0.517~0.771)。结果如图1。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>心房颤动作为临床最常见的心律失常之一，基于肺静脉隔离的导管消融术是目前维持房颤患者窦性心律的重要方法，可明显改善患者症状。2020年欧洲心脏协会(ESC)心房颤动诊治指南将导管消融治疗作为对有症状的阵发性心房颤动患者的I类推荐，对有症状的持续性心房颤动患者的IIa类推荐 [<xref ref-type="bibr" rid="hanspub.44888-ref5">5</xref>]，有研究表明射频消融治疗心房颤动优于单纯药物治疗 [<xref ref-type="bibr" rid="hanspub.44888-ref6">6</xref>]，在控制症状、维持窦性心律方面有显著的效果，但是导管消融术后存在一定复发率 [<xref ref-type="bibr" rid="hanspub.44888-ref7">7</xref>]，这常常导致患者接受性较差，也困扰着临床医生。</p><p>以往研究表明，炎症和氧化应激在房颤的发生和维持中起到重要作用 [<xref ref-type="bibr" rid="hanspub.44888-ref8">8</xref>]。同型半胱氨酸是机体含硫氨基酸的重要代谢产物，已有研究表明同型半胱氨酸水平升高可导致心肌肥大及心肌组织损伤，可预测心血管不良事件的风险 [<xref ref-type="bibr" rid="hanspub.44888-ref9">9</xref>]，其所含的巯基可引起氧化应激，同时在自身氧化过程中也会产生大量自由基和氧化物，引起氧化应激反应 [<xref ref-type="bibr" rid="hanspub.44888-ref10">10</xref>]。Yao等 [<xref ref-type="bibr" rid="hanspub.44888-ref11">11</xref>] 研究报道，Hcy可诱导IL-6、IL-8、IL-1β表达，引起炎症反应，促进心肌纤维化，引起房颤。也有研究认为，血清尿酸水平升高可增加氧化应激，并直接损伤内皮功能，同时促进炎性反应进一步加重，导致蛋白质变性、细胞坏死、线粒体功能障碍，造成心房的成纤维细胞增殖、迁移、分化，导致心房纤维化，引起心房结构重构和电重构 [<xref ref-type="bibr" rid="hanspub.44888-ref12">12</xref>]。Tamariz等 [<xref ref-type="bibr" rid="hanspub.44888-ref13">13</xref>] 研究发现尿酸是新发房颤的独立危险因素。Canpola等 [<xref ref-type="bibr" rid="hanspub.44888-ref14">14</xref>] 研究结果表明，术前血清尿酸水平与术后房颤复发有显著的相关性，可以作为预测术后复发的独立预测因子。本研究也发现，在房颤复发组和未复发组中，血清同型半胱氨酸和血清尿酸水平存在显著差异，而Logistic回归分析表明，血清尿酸水平是术后房颤复发的独立危险因素。</p><p>图1. 左房前后径、左房容积指数、是否存在左房低电压区、血清尿酸水平预测术后房颤复发的ROC曲线分析</p><p>左心房低电压区表明左心房纤维化导致的组织耦合不良、电传导不连续、组织各向异性，反映心房纤维化的程度 [<xref ref-type="bibr" rid="hanspub.44888-ref15">15</xref>]。刘玉婷等人 [<xref ref-type="bibr" rid="hanspub.44888-ref16">16</xref>] 以&lt;0.5 mV作为低电压临界值，通过术中双极电压标测时标记左心房低电压区，间接反映房颤患者的纤维化及程度，研究发现年龄与是否存在左房低电压区相关，且左房低电压区是房颤射频消融术后复发的独立危险因素。这与本研究的结果一致。</p><p>左房前后径是通过超声心动图衡量左心房体积的重要指标，左心房扩大反映左心房结构重构的程度，可导致心房内电传导异常，增加房颤发生的几率 [<xref ref-type="bibr" rid="hanspub.44888-ref17">17</xref>]。有Meta分析显示：房颤射频消融术后复发组较未复发患者左房内径平均增加1.87 mm，差异有统计学意义，证实术前左房扩大是房颤复发的危险因素 [<xref ref-type="bibr" rid="hanspub.44888-ref18">18</xref>]。左房容积指数消除了身高、体重的影响，比左房前后径更能反映个体左房体积的改变 [<xref ref-type="bibr" rid="hanspub.44888-ref19">19</xref>]。有研究显示，房颤射频消融术后复发的患者其左房容积指数较未复发患者更大，且左房容积指数是房颤术后复发的危险因数 [<xref ref-type="bibr" rid="hanspub.44888-ref20">20</xref>]。本研究也发现，左房前后径、左房容积指数与射频消融术后房颤复发相关。</p><p>本研究通过回顾性分析射频消融术后复发组与未复发组的临床资料，结果显示患者房颤类型为持续性房颤、病程、左房前后径、左房容积指数、左心室射血分数、术中标测是否存在左心房低电压区、血清尿酸水平、血清同型半胱氨酸水平与术后房颤复发有关。多因素Logistic回归分析发现左房前后径、左房容积指数、左房低电压区、血清尿酸水平与射频消融术后房颤复发相关。同时也应当认识到，本研究为回顾性研究，且样本数较少，研究结果存在一定局限性，尚缺乏大型临床随机对照实验数据支持。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，房颤患者左房前后径、左房容积指数、是否存在左房低电压区、血清尿酸与射频消融术后房颤复发独立相关，左房前后径大、左房容积指数高、存在左房低电压区、血清尿酸高可以预测房颤患者术后复发。早期监测并给予适当干预可能有效预防术后房颤复发。</p></sec><sec id="s10"><title>文章引用</title><p>李凯杨,王茂敬,蔡尚郎. 心房颤动患者射频消融术后复发的危险因素研究Study on Risk Factors for Recurrence after Radiofrequency Ablation in Patients with Atrial Fibrillation[J]. 临床医学进展, 2021, 11(08): 3806-3812. https://doi.org/10.12677/ACM.2021.118559</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44888-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Z.Q. and Hu, D.Y. (2008) An Epidemiological Study on the Prevalence of Atrial Fibrillation in the Chinese Population of Mainland China. Japan Epidemiological Association, 18, 209-216.  
&lt;br&gt;https://doi.org/10.2188/jea.JE2008021</mixed-citation></ref><ref id="hanspub.44888-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Craig, T.J., Wann, L.S., Calkins, H., Chen, L.Y., Cigarroa, J.E., Cleveland, J.C., Ellinor, P.T., Ezekowitz, M.D., Field, M.E., Furie, K.L., Heidenreich, P.A., Murray, K.T., Shea, J.B., Tracy, C.M. and Yancy, C.W. (2019) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. Circulation, 140, e125-e151.</mixed-citation></ref><ref id="hanspub.44888-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Aryana, Arash., Chierchia, G.-B. and de Asmundis, C. (2020) Recurrent Atrial Fibrillation after Cryoballoon Ablation: What to Expect! Cardiac Electrophysiology Clinics, 12, 199-208.</mixed-citation></ref><ref id="hanspub.44888-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">陈伟刚, 张守彦, 谷云飞, 金军, 齐玉婕, 吴鹏宇. 血清同型半胱氨酸、射血分数及左房容积指数与心房颤动射频消融术后复发的相关性研究[J]. 中国循证心血管医学杂志, 2021, 13(4): 421-424.</mixed-citation></ref><ref id="hanspub.44888-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., et al. (2021) 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 42, 373-498. &lt;br&gt;https://doi.org/10.1093/eurheartj/ehaa612</mixed-citation></ref><ref id="hanspub.44888-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Jonathan, M.K., Prashanthan, S., Raphael, R. and Hugh, C. (2017) Should We Perform Catheter Ablation for Asymptomatic Atrial Fibrillation? Circulation, 136, 490-499.</mixed-citation></ref><ref id="hanspub.44888-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Prystowsky, E.N., Padanilam, B.J. and Fogel, R.I. (2015) Treatment of Atrial Fibrillation. JAMA, 314, 278-288.  
&lt;br&gt;https://doi.org/10.1001/jama.2015.7505</mixed-citation></ref><ref id="hanspub.44888-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Basil, S.K., Alejandro, C.-M., Wonjoon, K., Joseph, G.A. and Fadi, G.A. (2017) Oxidative Stress and Inflammation as Central Mediators of Atrial Fibrillation in Obesity and Diabetes. Cardiovascular Diabetology, 16, 120. 
&lt;br&gt;https://doi.org/10.1186/s12933-017-0604-9</mixed-citation></ref><ref id="hanspub.44888-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Fu, Y., Wang, X. and Kong, W. (2018) Hyperhomocysteinaemia and Vascular Injury: Advances in Mechanisms and Drug Targets. British Journal of Pharmacology, 175, 1173-1189. &lt;br&gt;https://doi.org/10.1111/bph.13988</mixed-citation></ref><ref id="hanspub.44888-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Yao, Y., Shang, M.-S., Gao, L.-J., Zhao, J.-H., et al. (2017) Elevated Homocysteine Increases the Risk of Left Atrial/Left Atrial Appendage Thrombus in Non-Valvular Atrial Fibrillation with Low CHA2DS2—VASc Score. Europace, 20, 1093-1098. &lt;br&gt;https://doi.org/10.1093/europace/eux189</mixed-citation></ref><ref id="hanspub.44888-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yao, Y., Shang, M.-S., Dong, J.-Z. and Ma, C.-S. (2017) Homocysteine in Non-Valvular Atrial Fibrillation: Role and Clinical Implications. Clinica Chimica Acta, 475, 85-90. &lt;br&gt;https://doi.org/10.1016/j.cca.2017.10.012</mixed-citation></ref><ref id="hanspub.44888-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chao, T.-F., Hung, C.-L., Chen, S.-J., Wang, K.-L., et al. (2013) The Association between Hyperuricemia, Left Atrial Size and New-Onset Atrial Fibrillation. International Journal of Cardiology, 168, 4027-4032. 
&lt;br&gt;https://doi.org/10.1016/j.ijcard.2013.06.067</mixed-citation></ref><ref id="hanspub.44888-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Leonardo, T., Sunil, A., Elsayed, Z.S., Alanna, M.C., et al. (2011) Association of Serum Uric Acid with Incident Atrial Fibrillation (from the Atherosclerosis Risk in Communities [ARIC] Study). The American Journal of Cardiology, 108, 1272-1276. &lt;br&gt;https://doi.org/10.1016/j.amjcard.2011.06.043</mixed-citation></ref><ref id="hanspub.44888-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Canpolat, U., Aytemir, K., Yorgun, H., Şahiner, L., et al. (2014) Usefulness of Serum Uric Acid Level to Predict Atrial Fibrillation Recurrence after Cryoballoon-Based Catheter Ablation. Europace, 16, 1731-1737. 
&lt;br&gt;https://doi.org/10.1093/europace/euu198</mixed-citation></ref><ref id="hanspub.44888-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Jons, C., Jacobsen, U.G., Joergensen, R.M., Olsen, N.T., et al. (2011) The Incidence and Prognostic Significance of New-Onset Atrial Fibrillation in Patients with Acute Myocardial Infarction and Left Ventricular Systolic Dysfunction: A Carisma Substudy. Heart Rhythm, 8, 342-348. &lt;br&gt;https://doi.org/10.1016/j.hrthm.2010.09.090</mixed-citation></ref><ref id="hanspub.44888-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">刘玉婷. 非瓣膜性心房颤动射频消融患者左心房低电压与临床危险因素及术后复发相关性研究[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2020.</mixed-citation></ref><ref id="hanspub.44888-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">史琳, 杨传华. 老年高血压患者血压控制水平、心脏结构及功能与心房颤动发生的相关性[J]. 中国老年学杂志, 2018, 38(11): 2583-2585.</mixed-citation></ref><ref id="hanspub.44888-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">李茹哲, 张烁. 房颤导管消融术后复发相关预测因素[J]. 心血管康复医学杂志, 2018, 27(1): 93-96.</mixed-citation></ref><ref id="hanspub.44888-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">刘佳, 吕秀章. 二维及实时三维超声心动图测量阵发性心房颤动患者左房容积的相关性研究[J]. 临床超声医学杂志, 2017, 19(9): 610-613.</mixed-citation></ref><ref id="hanspub.44888-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Njoku, A., Kannabhiran, M., Arora, R., Reddy, P., et al. (2018) Left Atrial Volume Predicts Atrial Fibrillation Recurrence after Radiofrequency Ablation: A Meta-Analysis. Europace, 20, 33-42. &lt;br&gt;https://doi.org/10.1093/europace/eux013</mixed-citation></ref></ref-list></back></article>